Insights Into Prostate Cancer 2023

Perspectives on drivers in treatment decisions in the management of prostate cancer

Southeast – March 11, 2023
Purchase Report

Faculty Chair

Mehmet Asim Bilen, MD

Winship Cancer Institute, Atlanta, GA, USA

Southwest – March 22, 2023
Purchase Report

Faculty Chair

Rana McKay, MD

University of California San Diego Medical Center, San Diego, CA, USA

Central – April 21 2023
Purchase Report

Faculty Chair

Ananth Arjunan, MD

Texas Oncology, Dallas, TX

Midwest – August 25, 2023
Purchase Report

Faculty Chair

Russell Szmulewitz, MD

UChicago Medicine, Chicago, IL, USA

Northeast – October 13, 2023
Purchase Report

Faculty Chair

Atish Choudhury, MD, PhD

Dana-Farber Cancer Institute, Boston, MA, USA

Northwest – November 18, 2023
Purchase Report

Faculty Chair

Terence Friedlander, MD

UCSF Health, Francisco, CA, USA

More Information

  • Atlanta, GA
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Dallas, TX
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Chicago, IL
  • Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of prostate cancer
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: apalutamide, darolutamide, enzalutamide, androgen deprivation therapy, docetaxel, abiraterone, and combinations of these drugs

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.